India's Biocon developing its own version of Wegovy, clinical trial likely next year

Philippines News News

India's Biocon developing its own version of Wegovy, clinical trial likely next year
Philippines Latest News,Philippines Headlines
  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 63%

Explore stories from Atlantic Canada.

Prices at the Pumps - April 17, 2024 #saltwire #energymarkets #pricesatthepumps #gaspricesHYDERABAD - Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters.

Semaglutide will lose patent protection in those countries in 2026, Mittal said, adding that the company is talking to local manufacturers regarding partnerships to ensure supply. The company is also developing a version of tirzepatide, the active ingredient in Eli Lilly's rival obesity treatment Mounjaro and Zepbound, Mittal said, without providing details on the timing or initial marketing strategy.

Novo has so far launched Wegovy in a few wealthy countries, but said it aims to bring the drug to India by 2026.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

SaltWire Network /  🏆 45. in CA

Philippines Latest News, Philippines Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

India's Biocon developing its own version of Wegovy, clinical trial likely next yearIndia's Biocon developing its own version of Wegovy, clinical trial likely next yearExplore stories from Atlantic Canada.
Read more »

Biocon Leads India Push Into Weight Loss Drugs as Patents LapseBiocon Leads India Push Into Weight Loss Drugs as Patents LapseBiocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that’s expected to touch $100 billion by 2030.
Read more »

Novo ready to seek German insurance coverage of Wegovy for heart useNovo ready to seek German insurance coverage of Wegovy for heart useExplore stories from Atlantic Canada.
Read more »

Novo ready to seek German insurance coverage of Wegovy for heart useNovo ready to seek German insurance coverage of Wegovy for heart useExplore stories from Atlantic Canada.
Read more »

Wegovy gains Medicare, Medicaid coverage for heart benefitsWegovy gains Medicare, Medicaid coverage for heart benefitsNovo Nordisk's (NVO) weight-loss medication, Wegovy, will now be covered by Medicare and Medicaid. This decision comes in light of the drug's demonstrated...
Read more »

Germany's health insurance could cover Wegovy for strokes, heart conditions, agency saysGermany's health insurance could cover Wegovy for strokes, heart conditions, agency saysExplore stories from Atlantic Canada.
Read more »



Render Time: 2025-02-26 14:24:31